美国 · SEC FORM 4
Celularity Inc
CELU · Nasdaq · CIK 0001752828 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
0 同一窗口内观察到的 Form 4 交易行
0 sales · 0 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
当前 180 天窗口内没有 Form 4 交易事件。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-01-12 · Dragasac Ltd; Genting Berhad; Lim Kok Thay.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 391,276
- 上期报告
- 821,020
- 日均成交量
- 154,929
- 回补天数
- 2.5
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-01-12 | Dragasac Ltd; Genting Berhad; Lim Kok Thay | 买入 (P) | Class A Common Stock | 21,410,983 | USD 0.25 | USD 5,352,746 | SEC 申报 ↗ |
| 2023-10-05 | Hariri Robert J | 买入 (P) | Class A Common Stock | 9,357,585 | USD 0.16 | USD 1,497,214 | SEC 申报 ↗ |
| 2023-09-29 | Hariri Robert J | 买入 (P) | Class A Common Stock | 9,064,539 | USD 0.17 | USD 1,540,972 | SEC 申报 ↗ |
| 2022-11-30 | Hariri Robert J | 买入 (P) | Class A Common Stock | 10,000 | USD 1.72 | USD 17,200 | SEC 申报 ↗ |
| 2022-11-29 | Hariri Robert J | 买入 (P) | Class A Common Stock | 40,000 | USD 1.71 | USD 68,400 | SEC 申报 ↗ |
| 2022-11-28 | Hariri Robert J | 买入 (P) | Class A Common Stock | 40,000 | USD 1.74 | USD 69,600 | SEC 申报 ↗ |
Form 4 申报证据
25 transaction lines in the latest 365-day window; 130 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-04-13 | Hariri Robert J | 期权行权／转换 (M) | Class A Common Stock | 3,281 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-13 | Hariri Robert J | 代扣税 (F) | Class A Common Stock | 1,182 | USD 1.28 | USD 1,513 | SEC 申报 ↗ |
| 2026-04-13 | Haines John R | 期权行权／转换 (M) | Class A Common Stock | 1,641 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (25 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-04-13 | Hariri Robert J | 期权行权／转换 (M) | Class A Common Stock | 3,281 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-13 | Hariri Robert J | 代扣税 (F) | Class A Common Stock | 1,182 | USD 1.28 | USD 1,513 | SEC 申报 ↗ |
| 2026-04-13 | Haines John R | 期权行权／转换 (M) | Class A Common Stock | 1,641 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-13 | Haines John R | 代扣税 (F) | Class A Common Stock | 583 | USD 1.28 | USD 746 | SEC 申报 ↗ |
| 2026-04-13 | Brigido Stephen | 期权行权／转换 (M) | Class A Common Stock | 821 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-13 | Brigido Stephen | 代扣税 (F) | Class A Common Stock | 268 | USD 1.28 | USD 343 | SEC 申报 ↗ |
| 2026-01-12 | Parks Diane L. | 奖励／授予 (A) | Class A Common Stock | 30,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-12 | Ling Geoffrey M.D. | 奖励／授予 (A) | Class A Common Stock | 19,231 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-12 | LeVien Vincent | 奖励／授予 (A) | Class A Common Stock | 28,847 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-12 | Diamandis Peter | 奖励／授予 (A) | Class A Common Stock | 20,385 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-12 | Parks Diane L. | 奖励／授予 (A) | Class A Common Stock | 30,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-12 | Ling Geoffrey M.D. | 奖励／授予 (A) | Class A Common Stock | 19,231 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-12 | LeVien Vincent | 奖励／授予 (A) | Class A Common Stock | 28,847 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-12 | Diamandis Peter | 奖励／授予 (A) | Class A Common Stock | 20,385 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-29 | Parks Diane L. | 奖励／授予 (A) | Class A Common Stock | 125,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-29 | Ling Geoffrey M.D. | 奖励／授予 (A) | Class A Common Stock | 125,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-29 | LeVien Vincent | 奖励／授予 (A) | Class A Common Stock | 125,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-29 | Diamandis Peter | 奖励／授予 (A) | Class A Common Stock | 125,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-19 | Parks Diane L. | 奖励／授予 (A) | Class A Common Stock | 67,416 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-19 | Ling Geoffrey M.D. | 奖励／授予 (A) | Class A Common Stock | 67,416 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-19 | Diamandis Peter | 奖励／授予 (A) | Class A Common Stock | 67,416 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-11-19 | Parks Diane L. | 奖励／授予 (A) | Class A Common Stock | 61,539 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-11-19 | Ling Geoffrey M.D. | 奖励／授予 (A) | Class A Common Stock | 44,379 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-11-19 | LeVien Vincent | 奖励／授予 (A) | Class A Common Stock | 3,699 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-11-19 | Diamandis Peter | 奖励／授予 (A) | Class A Common Stock | 47,042 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | CELU |
| CIK | 0001752828 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 130 transaction lines from 2021-07-16 to 2026-04-13 7 P purchase lines · 2 S sale lines · 121 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.